News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Otsuka Pharmaceutical Co., Ltd. Acquires Rights To Hematological Cancer Treatment Dacogen® From Eisai Inc. (ESALF.PK) (U.S.)


3/31/2014 8:21:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) has announced an agreement with Eisai Inc. (Eisai), a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment DacogenĀ® and to an enzyme inhibitor, E7727.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES